Science & Technology
SBIR Phase II:Formulation of a mRNA-Based Therapy for CTLN1 by Inverse Flash NanoPrecipitation
National Science Foundation
Opportunity #: 2233286
Award Ceiling
$1.0M
Award Floor
$1.0M
Close Date
Jun 30, 2025
Total Funding
$1.0M
Expected Awards
1
Posted Date
Jul 15, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-2233286
Description
SBIR Phase Phase II award: "SBIR Phase II:Formulation of a mRNA-Based Therapy for CTLN1 by Inverse Flash NanoPrecipitation" awarded to Optimeos Life Sciences, Inc. in PRINCETON, New Jersey. Funded by National Science Foundation. Award amount: $1,000,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.